News | Molecular Imaging | June 29, 2015

North America Accounts for Highest Share of Global Nuclear Medicine Diagnostic Market

Fusion imaging and wide availability of radiopharmaceuticals expected to push market up nearly $7 billion by 2019

nuclear medicine diagnostic market, North America, PET, SPECT, Mordor

June 29, 2015 - The Global Nuclear Medicine Diagnostics Market report from Mordor Intelligence revealed that North America accounts for the highest share of the global nuclear medicine diagnostic market, followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in the diagnostic sector because of increasing diagnostic procedure demand and the rise of the medical device industry.

The market is segmented into two major segments: single photon emission computed tomography (SPECT), which includes technetium-99m (TC-99m), thallium-201 (TL-201), iodine (I-123) and others; and positron emission tomography (PET), including fluorine-18, rubidium-82 (RB-82) and others. By application the market is segmented into SPECT (cardiology, lymphoma, thyroid, neurology and others) and PET (oncology, cardiology, neurology and others). By geography the market is segmented into North America, Europe and Asia-Pacific etc.

The global nuclear medicine diagnostic (PET and SPECT) market is expected to grow from an estimated $ 8.77 billion in 2014 to $15.51 billion in 2019, at an estimated compound annual growth rate (CAGR) of 12.08 percent.

Major factors for the growth of the market are increasing use of SPECT and PET in medical diagnostics, increased awareness about radiopharmaceuticals and ready availability of radiopharmaceuticals. It has novel applications for diseases such as Alzheimer's and a continually expanding oncology segment. However, some of the major constraints for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues.

Until now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of a global shortage of molybdenum-99 isotope, which in turn will lead to a shortage of technetium-99, the daughter product of molybdenum. Hence, PET imaging products, which includes hybrid PET-CT scanners, holds a potential increase in market size in coming years. The cost associated with PET-CT service contracts is usually 105 percent of the system purchase price annually and can be as high as $275,000 per year.

The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET (magnetic resonance imaging). This provides a full gamut of imaging scans through the same unit and at the same time. The PET market is expected to witness more growth compared to SPECT imaging, as it provides higher resolution images, and the lack of availability of technetium-99m is propelling the industry to look for alternative diagnostic procedures.

Analyzing the application segment of SPECT and PET, PET is majorly being used in oncology because of good quality of imaging. SPECT, however, is mostly being used in the cardiology segment, accounting for almost 90 percent of the market share in cardiology. North America has totaled 5,729 PET procedures, while the number of PET procedures in the Asia-Pacific region is 369,636, owing to the increased demand of nuclear medicine diagnostic procedures in developing nations.

Major players in the market include Cardiarc Ltd., Digirad Corp., Gamma Medica Inc., GE Healthcare and Hologic Inc. Mergers and acquisitions of small and medium-sized manufacturers is another strategy being adopted by multinational players to enter in overseas markets.

For more information: www.mordorintelligence.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init